Molina Healthcare
MOH
$176.20
-4.31%
Molina Healthcare, Inc. is a managed care company that provides government-sponsored healthcare programs, primarily Medicaid, Medicare, and Marketplace (ACA exchange) plans. The company is a significant player in the Medicaid managed care space, with over 85% of its more than 5 million members coming from state government contracts, notably in California, New York, Texas, and Washington. The current investor narrative is dominated by the volatile interplay between regulatory reimbursement dynamics and operational execution, with recent news highlighting a boost to Medicare Advantage payments from CMS. This follows a period of significant stock price volatility, driven by a sharp sell-off in early February 2026, reflecting intense scrutiny on medical cost trends, profitability in its core Medicaid segment, and the company's ability to navigate a complex regulatory environment.…
MOH
Molina Healthcare
$176.20
Investment Opinion: Should I buy MOH Today?
Rating: Hold. The core thesis is that while the stock is deeply undervalued on a sales basis, the severe and recent deterioration in profitability and cash flow requires a 'show me' period before a Buy rating is justified.
Supporting this Hold rating are four key data points: 1) The valuation is at a historical trough with a PS ratio of 0.19, suggesting limited further multiple compression. 2) Revenue growth remains positive at 8.34% YoY, providing a top-line foundation. 3) Analyst EPS estimates for the next period average $21.81, implying a forward P/E of ~8.4x based on the current price, which is cheap if achievable. 4) The stock has shown strong short-term momentum (+20% in 1 month), indicating some investor belief in a bottom.
The thesis would upgrade to a Buy on two conditions: 1) A return to consistent positive quarterly free cash flow, and 2) Gross margin stabilization and recovery above 9%. It would downgrade to a Sell if quarterly cash burn accelerates or if revenue growth turns negative. Relative to its own history and the distressed fundamentals, the stock is fairly valued; it is not undervalued enough to ignore the cash burn, nor overvalued given the potential for a cyclical recovery in managed care margins.
Sign up to view all
MOH 12-Month Price Forecast
The investment case for MOH is a binary bet on operational turnaround. The valuation is compelling, but it is justified by catastrophic recent fundamentals. The base case of a messy, protracted recovery is most likely. The stance would upgrade to bullish on confirmation of margin stabilization and a return to positive cash flow, likely after the next 1-2 quarterly reports. It would turn bearish if the next quarter shows a continuation or worsening of the Q4 2025 cost trends. The recent CMS news is a sector-wide positive but does not directly solve Molina's specific Medicaid cost issues.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Molina Healthcare's 12-month outlook, with a consensus price target around $229.06 and implied upside of +30.0% versus the current price.
Average Target
$229.06
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$141 - $229
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, indicating this is not a widely followed large-cap name. The consensus sentiment appears cautious to negative, as evidenced by recent rating actions; for instance, Wells Fargo downgraded the stock from Overweight to Equal Weight in February 2026. The average revenue estimate for the next period is $52.61 billion, with an average EPS estimate of $21.81. Insufficient data is provided to calculate a precise average price target or a clear Buy/Hold/Sell distribution. The limited coverage and lack of a published consensus price target typically signal higher uncertainty and less efficient price discovery, which can contribute to the stock's heightened volatility. The wide range in EPS estimates, from a low of $20.51 to a high of $23.50, further underscores the uncertainty surrounding the company's near-term earnings recovery path. The absence of a strong bullish consensus and the recent downgrades suggest the analyst community is waiting for clearer signs of a fundamental turnaround before becoming more constructive.
Bulls vs Bears: MOH Investment Factors
The evidence currently tilts bearish due to severe fundamental deterioration, specifically the collapse in profitability and negative cash flow, which are primary drivers of value. However, the bull case is supported by an extreme valuation discount and a nascent technical recovery. The single most important tension in the investment debate is whether the catastrophic Q4 2025 results represent a one-time operational failure or a structural breakdown in Molina's ability to manage medical costs within its government-contracted business model. The resolution of this tension, evidenced by a return to positive cash flow and stable margins, will determine if the stock is a deep-value turnaround or a value trap.
Bullish
- Extreme Valuation Discount: The stock trades at a historically low Price-to-Sales (PS) ratio of 0.19, a dramatic de-rating from multiples above 2.0x seen in early 2024. This deep value multiple suggests the market has priced in a worst-case scenario, leaving significant room for multiple expansion if fundamentals stabilize.
- Strong Recent Price Momentum: The stock is up 20.35% over the past month and 21.95% over the past three months, indicating a powerful relief rally from oversold conditions. This technical recovery, diverging from the -40.56% 1-year trend, suggests potential capitulation and a trend reversal.
- Revenue Growth Remains Intact: Despite profitability issues, quarterly revenue grew 8.34% year-over-year to $11.38 billion. Analyst consensus expects continued top-line growth to $52.61 billion, providing a stable foundation for a potential turnaround.
- Positive Sector Catalyst (CMS Payments): Recent news of a larger-than-expected 2027 Medicare Advantage payment increase from CMS provides a positive sentiment catalyst for the entire managed care sector, potentially improving revenue visibility for Molina's Medicare segment.
Bearish
- Severe Profitability Collapse: The company swung to a Q4 2025 net loss of -$160 million (-$3.15 EPS) from a profit of $251 million ($4.37 EPS) a year ago. Gross margin collapsed to 6.16% from 10.6%, driven by sharply higher medical costs, raising existential questions about its business model.
- Persistent Negative Cash Flow: Trailing twelve-month free cash flow is -$636 million, and the latest quarter saw operating cash flow of -$298 million. This cash burn is a critical red flag, indicating the company is not self-funding and raising sustainability concerns.
- Analyst Downgrade & Uncertainty: Analyst coverage is limited (only 5 analysts) and sentiment is cautious, with a recent Wells Fargo downgrade from Overweight to Equal Weight. The wide EPS estimate range ($20.51 to $23.50) underscores high uncertainty around an earnings recovery.
- Deep Technical Damage: The stock remains 41.2% below its 52-week high of $312.85, having experienced a -63.06% maximum drawdown. Despite recent gains, it trades just 20.2% above its 52-week low, reflecting a stock that has suffered a fundamental re-rating.
MOH Technical Analysis
The stock is in a pronounced downtrend over the past year, evidenced by a 1-year price change of -40.56%. The current price of $184.14 sits just 20.2% above its 52-week low of $121.06, placing it in the lower 20th percentile of its annual range, which suggests a deeply oversold condition or a potential value opportunity following a severe correction. However, it remains a significant 41.2% below its 52-week high of $312.85, indicating substantial technical damage has been sustained. Recent momentum shows a powerful short-term recovery, with the stock up 20.35% over the past month and 21.95% over the past three months, sharply diverging from the longer-term downtrend. This divergence suggests a potential trend reversal or a significant relief rally from deeply oversold levels, though it has not yet reclaimed the levels preceding the February collapse. Key technical support is clearly defined at the 52-week low of $121.06, while initial resistance lies at the recent recovery high near $201.89 from late January. A sustained breakout above this $200 level would signal a more robust recovery is underway. The stock's beta of 0.85 indicates it is 15% less volatile than the broader market (SPY), which is notable given its recent sharp price swings; this lower beta suggests the stock's extreme moves are driven by idiosyncratic, company-specific factors rather than broad market sentiment.
Beta
0.85
0.85x market volatility
Max Drawdown
-63.1%
Largest decline past year
52-Week Range
$121-$312
Price range past year
Annual Return
-42.3%
Cumulative gain past year
| Period | MOH Return | S&P 500 |
|---|---|---|
| 1m | +0.1% | +5.1% |
| 3m | +21.1% | +8.3% |
| 6m | +18.8% | +10.4% |
| 1y | -42.3% | +29.6% |
| ytd | -1.3% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MOH Fundamental Analysis
Revenue growth has been consistent but modest, with the most recent quarterly revenue of $11.38 billion representing an 8.34% year-over-year increase. However, the growth trajectory has been overshadowed by severe profitability issues. The company swung to a significant net loss of -$160 million in Q4 2025, with a gross margin of just 6.16%, a stark deterioration from the 10.6% gross margin in the year-ago quarter. This quarterly loss of -$3.15 EPS contrasts sharply with the positive net income of $251 million ($4.37 EPS) in Q4 2024, indicating a sharp compression in profitability driven by higher medical costs. The balance sheet and cash flow position present significant concerns. The trailing twelve-month free cash flow is deeply negative at -$636 million, and the most recent quarter saw operating cash flow of -$298 million and free cash flow of -$297 million. This indicates the company is not generating sufficient internal cash to fund operations, a critical red flag. While the current ratio of 1.69 and a debt-to-equity ratio of 0.97 show adequate short-term liquidity and manageable leverage, the persistent negative cash flow raises questions about long-term financial sustainability if not corrected. Return on Equity (ROE) for the trailing period stands at 11.6%, but this metric is likely inflated by the low equity base following the recent quarterly loss and may not be sustainable given the current cash burn.
Quarterly Revenue
$11.4B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$-636000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MOH Overvalued?
Given the negative net income in the most recent quarter, the primary valuation metric selected is the Price-to-Sales (PS) ratio, as profitability-based metrics like P/E are not meaningful. The trailing PS ratio is 0.19, while the forward PS, implied by the market cap of $8.81 billion and analyst revenue estimates of $52.61 billion, is approximately 0.17. This minimal gap suggests the market is not pricing in significant sales growth or margin recovery. Compared to industry averages, a sub-0.2x PS ratio is exceptionally low for a managed care company, typically indicating deep value or significant fundamental distress. Historically, Molina's own valuation has collapsed; its PS ratio of 0.19 is near the bottom of its multi-year range, having traded above 2.0x as recently as early 2024. This dramatic de-rating from historical highs reflects the market's severe discount for the recent collapse in profitability and negative cash flows. The current valuation near historical lows suggests the stock is pricing in a worst-case scenario, but it also implies that any recovery in margins or cash flow generation could lead to substantial multiple expansion.
PE
18.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -14x~86x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and immediate. The company's Q4 2025 gross margin of 6.16% represents a 420 basis point year-over-year collapse, directly causing a -$160 million net loss. This margin pressure is compounded by a TTM free cash flow burn of -$636 million, indicating the business is consuming cash to fund operations. With revenue concentration in volatile state Medicaid contracts (over 85% of members), earnings are highly exposed to reimbursement rate negotiations and unexpected medical cost inflation, as evidenced by the recent quarter.
Market & Competitive Risks center on a valuation that, while deeply discounted, may not recover. The stock's PS ratio of 0.19 is at a historical nadir, having de-rated from over 2.0x. This compression reflects a loss of investor confidence that may persist even if fundamentals improve modestly. The stock's beta of 0.85 suggests its recent -40.56% annual decline was largely idiosyncratic, driven by company-specific execution failures rather than sector-wide headwinds, making a recovery reliant solely on internal fixes. Competitive pressure from larger, more diversified managed care peers could further squeeze margins.
Worst-Case Scenario involves a continuation of the Q4 2025 cost trend, leading to further quarterly losses, a depletion of liquidity, and potential breaches of regulatory capital requirements for its insurance subsidiaries. This could trigger a crisis of confidence, analyst downgrades, and a re-test of the 52-week low of $121.06. From the current price of $184.14, this scenario implies a downside of approximately -34%. A more severe scenario, involving the loss of a major state contract, could drive the stock below the $100 level, representing a loss greater than -45%.
FAQ
The key risks are, in order of severity: 1) Financial Sustainability Risk: Persistent negative free cash flow (-$636M TTM) could strain liquidity. 2) Profitability Risk: The collapse in Q4 gross margin to 6.16% may be structural, not temporary. 3) Operational Risk: Over 85% reliance on government Medicaid contracts exposes earnings to volatile reimbursement rates and cost trends. 4) Sentiment Risk: Limited analyst coverage (5 analysts) and a recent downgrade reflect high uncertainty, which can lead to sharp price swings like the -63% max drawdown already experienced.
The 12-month outlook is highly bifurcated. Our base case (50% probability) sees the stock trading between $180 and $220 as it grapples with a slow, partial recovery. The bull case (25% probability), involving a return to profitability, could drive the stock to $230-$280. The bear case (25% probability), where problems persist, could see a re-test of the 52-week low near $121. The most likely scenario is the base case, predicated on the assumption that medical cost pressures ease but the company struggles to fully regain its former margin profile in the near term.
MOH is deeply undervalued on a sales basis but may be fairly valued or overvalued on an earnings/cash flow basis. Its Price-to-Sales (PS) ratio of 0.19 is near historical lows and well below industry averages, suggesting undervaluation. However, with negative earnings and cash flow, traditional P/E and P/CF metrics are negative or meaningless. The valuation implies the market expects continued poor profitability. It is a 'cigar butt' valuation—cheap for a reason—with the discount reflecting real, severe fundamental problems.
MOH is a speculative buy only for investors with a high risk tolerance and a long-term view. At a PS ratio of 0.19, it is priced for distress, offering significant upside if management can fix its medical cost issues. However, the recent -$160M quarterly loss and -$636M TTM free cash flow burn present substantial risk. The average analyst EPS estimate of $21.81 suggests the market is skeptical. It could be a good buy for deep-value investors betting on a turnaround, but it is not suitable for conservative portfolios.
MOH is unsuitable for short-term trading due to its high volatility driven by binary earnings outcomes and low analyst coverage. It is only appropriate for long-term investors (minimum 2-3 year horizon) who are betting on a multi-year operational turnaround. The stock's beta of 0.85 suggests it is less volatile than the market over time, but its recent price action shows extreme idiosyncratic risk. There is no dividend, so the entire return is dependent on price appreciation from a successful turnaround, which will take multiple quarters to confirm.